Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers that are potentially useful for the treatment of pain, urinary incontinence, multiple sclerosis, cough and arrhythmia.

Work at Shanghai 3D Medicines Laboratory Co. Ltd. has led to the discovery of new sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers designed for use in the treatment of pain.

Work at Alicorn Pharmaceutical Co. Ltd. has led to the synthesis of new sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers. They are reported to be useful for the treatment of pain, respiratory and neurological disorders.

Latigo Biotherapeutics Inc. has synthesized sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers. They are reported to be useful for the treatment of pain, cough and pruritus.

Jumpcan Pharmaceutical Group Ltd. has divulged sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.

Chengdu Easton Biopharmaceuticals Co. Ltd. has divulged sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arrhythmia, cough, urinary incontinence and multiple sclerosis.

Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have divulged aromatic compounds acting as sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.

Shanghai Innoxtal Therapeutics Co. Ltd. has disclosed sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain, arrhythmia and urinary incontinence.

Scientists at Apichope Bio Pharmaceutical Co. Ltd., Apichope Pharmaceutical Co. Ltd., Guangzhou Lianrui Pharmaceutical Co. Ltd. and Guangzhou Runlin Pharmaceutical Technology Co. Ltd. have synthesized sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers potentially useful for the treatment of pain, arrhythmia, cough, multiple sclerosis, urinary incontinence and Charcot-Marie-Tooth disease.

Solu Therapeutics Inc. has identified heterobifunctional cotinine-containing compounds acting as sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers or sodium channel protein type 9 subunit α (SCN9A; Nav1.7) blockers. They are reported to be useful for the treatment of pain, cough and pruritus.